European Ombudsman Inquiry on EMA pre-submission activities: EPF's response

The European Ombudsman's recent inquiry focuses on the level of transparency in the European Medicines Agency's pre-submission activities, and the appropriate extent of the use of "firewalls" in marketing authorisation applications.

Having been involved in various strands of the work of the EMA for many years, EPF is highly committed to the work of the Agency and familiar with its processes. 

Read our response to the inquiry here